Earnings summaries and quarterly performance for Ardent Health.
Executive leadership at Ardent Health.
Board of directors at Ardent Health.
ER
Edmondo Robinson
Detailed
Director
EH
Ellen Havdala
Detailed
Director
MS
Mark Sotir
Detailed
Chairman of the Board
PB
Peter Bulgarelli
Detailed
Director
PB
Peter Bynoe
Detailed
Director
RS
Rahul Sen
Detailed
Director
RW
Rob Webb
Detailed
Director
RA
Robert A. DeMichiei
Detailed
Director
SC
Suzanne Campion
Detailed
Director
WG
William Goodyear
Detailed
Director
Research analysts who have asked questions during Ardent Health earnings calls.
Benjamin Hendrix
RBC Capital Markets
4 questions for ARDT
Also covers: ACHC, ADUS, AHCO +25 more
BR
Benjamin Rossi
JPMorgan Chase & Co.
4 questions for ARDT
Also covers: AMED, AVAH, CON +7 more
CH
Craig Hettenbach
Morgan Stanley
4 questions for ARDT
Also covers: ACCD, AMWL, DH +10 more
MG
Matthew Gillmor
KeyCorp
4 questions for ARDT
Also covers: ACHC, ADUS, ALHC +11 more
AH
Ann Hynes
Mizuho Financial Group
2 questions for ARDT
Also covers: BTSG, CI, CNC +17 more
BM
Benjamin Mayo
Leerink Partners
2 questions for ARDT
Also covers: ACHC, AGL, AMED +10 more
JG
Joanna Gajuk
Bank of America
2 questions for ARDT
Also covers: ACHC, ADUS, AGL +21 more
SF
Scott Fidel
Stephens Inc.
2 questions for ARDT
Also covers: ACHC, ADUS, ALHC +17 more
TG
Timothy Greaves
Loop Capital Markets LLC
2 questions for ARDT
Also covers: PRCH, WEAV
Jason Cassorla
Guggenheim Partners
1 question for ARDT
Also covers: ACHC, CI, CYH +8 more
KF
Kevin Fischbeck
Bank of America
1 question for ARDT
Also covers: AMN, CCRN, CI +9 more
Raj Kumar
Stephens
1 question for ARDT
Also covers: ACHC, ADUS, AVAH +7 more
Whit Mayo
Leerink Partners
1 question for ARDT
Also covers: ACHC, AHCO, ALHC +11 more
Recent press releases and 8-K filings for ARDT.
Hagens Berman Investigates Ardent Health Following $97 Million Accounting Adjustments
ARDT
Legal Proceedings
Accounting Changes
Guidance Update
- Shareholder rights law firm Hagens Berman has initiated an investigation into Ardent Health, Inc. (NYSE: ARDT) for potential securities law violations after the company's Q3 2025 financial disclosures revealed significant adverse accounting adjustments.
- These adjustments totaled $97 million, comprising a $43 million reduction in revenue due to collectability estimates and a $54 million increase in professional liability reserves.
- The disclosures led to Ardent Health's stock price falling over 33%.
- The investigation focuses on whether company leadership failed to disclose material weaknesses in internal controls related to revenue recognition and liability reserves, and if these were long-standing issues.
- Additionally, the company made a significant cut to its 2025 Adjusted EBITDA guidance.
Dec 23, 2025, 2:30 PM
Ardent Health Under Investigation Following Q3 2025 Financial Disclosures
ARDT
Financial Restatement
Accounting Changes
Legal Proceedings
- Hagens Berman has launched an investigation into Ardent Health, Inc. (ARDT) following its Q3 2025 financial disclosures on November 12, 2025.
- The investigation focuses on adverse accounting adjustments totaling $97 million, which led to the stock plummeting over 33%.
- These adjustments include a $43 million revenue reduction related to collectability estimates and a $54 million increase in professional liability reserves.
- The firm is examining whether Ardent's leadership failed to disclose material weaknesses in internal controls concerning revenue recognition and liability reserves, alongside a significant cut to 2025 Adjusted EBITDA guidance.
Dec 16, 2025, 5:27 AM
Hagens Berman Investigates Ardent Health Over Accounting Adjustments
ARDT
Accounting Changes
Legal Proceedings
Guidance Update
- Shareholder rights law firm Hagens Berman has initiated an investigation into Ardent Health (ARDT) following the company's Q3 2025 financial disclosures.
- The investigation focuses on $97 million in adverse accounting adjustments, which include a $43 million revenue reduction and a $54 million increase in professional liability reserves.
- These disclosures, made on November 12, 2025, caused Ardent Health's stock to tumble over 33%.
- Hagens Berman is scrutinizing whether company leadership failed to disclose material weaknesses in internal controls related to revenue recognition and liability reserves, and the subsequent significant cut to 2025 Adjusted EBITDA guidance.
Dec 11, 2025, 2:30 PM
Ardent Health Investigated for Securities Violations
ARDT
Legal Proceedings
Accounting Changes
Profit Warning
- Bleichmar Fonti & Auld LLP is investigating Ardent Health, Inc. for potential violations of federal securities laws.
- The investigation centers on Ardent's alleged improper accounting for its accounts receivable and professional liability reserves.
- Ardent's stock dropped over 33% on November 13, 2025, following the release of its Q3 2025 financial results.
- The Q3 2025 results, reported on November 12, 2025, revealed a $43 million decrease in revenue and a $54 million increase in professional liability reserves.
Dec 3, 2025, 12:44 PM
Ardent Health Faces Investigation Over $97 Million Accounting Adjustments
ARDT
Legal Proceedings
Accounting Changes
Guidance Update
- Shareholder rights law firm Hagens Berman has initiated an investigation into Ardent Health (ARDT) for potential securities law violations after the company's Q3 2025 financial disclosures revealed $97 million in adverse accounting adjustments.
- These adjustments, which caused the stock to tumble over 33%, include a $43 million revenue reduction due to collectability estimates and a $54 million increase in professional liability reserves.
- The investigation focuses on whether Ardent's leadership failed to disclose material weaknesses in internal controls related to revenue recognition and liability reserves, and the significant cut to 2025 Adjusted EBITDA guidance.
Dec 3, 2025, 1:10 AM
Ardent Health Shares Decline Following Q3 2025 Results and Guidance Revision
ARDT
Earnings
Guidance Update
Legal Proceedings
- Ardent Health's shares tumbled $4.75 (-33%) on November 13, 2025, after the company announced its Q3 2025 financial results, which widely missed consensus EPS estimates and revealed two adverse non-recurring items.
- For Q3 2025, the company reported an EPS of -$0.17, a 189% decrease from the prior year period, and disclosed a $43 million adjustment that reduced revenue due to a modified technique for estimating accounts receivable collectability.
- Additionally, Ardent Health recorded a $54 million increase to its professional and general liability reserves, attributed to adverse prior period claim developments.
- The company significantly reduced its 2025 adjusted EBITDA guidance to $530-$550 million from $575-$615 million, representing a 9% decrease at the midpoint, partly blaming durable payor denials.
- Shareholder rights law firm Hagens Berman has opened an investigation into whether Ardent Health may have violated federal securities laws, focusing on the propriety of its financial statements, accounts receivable collectability, and professional liability reserves.
Nov 26, 2025, 1:50 PM
Ardent Health Reports Q3 2025 Results, Faces Investor Scrutiny
ARDT
Earnings
Profit Warning
Accounting Changes
- Ardent Health's shares tumbled $4.75 (-33%) on November 13, 2025, after the company announced its Q3 2025 financial results, which widely missed consensus EPS estimates.
- For Q3 2025, the company reported an EPS of -$0.17, a 189% decrease from the prior year period.
- The company revealed a $43 million adjustment that reduced revenue due to a modified technique for estimating accounts receivable collectability and a $54 million increase to its professional and general liability reserves.
- Ardent Health also reduced its 2025 adjusted EBITDA guidance to $530-$550 million from $575-$615 million, a 9% decrease at the midpoint, citing durable payor denials.
- Shareholder rights law firm Hagens Berman has opened an investigation into Ardent Health regarding potential violations of federal securities laws, focusing on the company's financial condition statements and accounting practices.
Nov 19, 2025, 9:56 PM
Ardent Health Announces $50 Million Share Repurchase Program
ARDT
Share Buyback
New Projects/Investments
- Ardent Health's Board of Directors authorized a $50 million share repurchase program on November 17, 2025.
- The program, which has no specified expiration date, will be funded from existing cash resources and ongoing cash from operations.
- As of the end of Q3 2025, Ardent Health reported a strong liquidity position with $609 million of cash and a lease-adjusted net leverage of 2.5x.
Nov 18, 2025, 9:14 PM
Ardent Health Discusses Growth Strategy, Margin Expansion, and Capital Deployment
ARDT
New Projects/Investments
Share Buyback
Guidance Update
- Ardent Health is pursuing a "tri-part growth thesis" focused on expanding its outpatient footprint, which has included adding over 27 urgent cares in the last year and a half, opportunistic M&A, and margin expansion, with confidence in achieving mid-single digit organic growth.
- The company has implemented "impact initiatives" with $40 million of activity already completed, primarily labor-related, which will be fully realized next year, and anticipates margins expanding to mid-teens over time despite industry headwinds like payer denials (almost 2x higher in managed products) and elevated professional fees.
- Ardent's board authorized a $50 million share repurchase, and the company plans to prioritize de novo Ambulatory Surgery Center (ASC) builds, which offer a more attractive growth algorithm (building at 2X multiple versus acquiring at 10X).
- Investments in technology, such as ambient listening, are being rolled out across the platform, with a pilot demonstrating a 4.5-hour reduction in documentation time per physician, aiming to enhance productivity and address workforce challenges.
Nov 18, 2025, 4:00 PM
Ardent Health Announces Share Repurchase and Discusses Growth Strategy, Headwinds
ARDT
Share Buyback
Guidance Update
New Projects/Investments
- Ardent Health announced a $50 million share repurchase authorization, viewing it as a prudent deployment of capital given its strong balance sheet, modest leverage of 2.5 times on a lease-adjusted basis, and over $800 million in available liquidity.
- The company's growth strategy focuses on expanding its outpatient footprint (having added over 27 urgent cares in the last 1.5 years), opportunistic M&A in mid-size urban markets, and margin expansion through "impact initiatives".
- Ardent is addressing industry headwinds including payer denials and elevated professional fees, particularly in radiology and anesthesiology, which have persisted longer and with greater intensity than expected.
- $40 million of impact initiatives have been completed, primarily labor-related through workforce optimization and contract renegotiation, which will contribute to Q4 and a full year impact next year, with further opportunities identified.
- The company remains confident in its long-term organic growth target of mid-single digits, potentially reaching high single digits with capital deployment, driven by population growth in its markets and outpatient expansion.
Nov 18, 2025, 4:00 PM
Quarterly earnings call transcripts for Ardent Health.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more